Adamas Pharmaceuticals Inc (NASDAQ:ADMS) – Equities researchers at William Blair lifted their FY2019 earnings per share (EPS) estimates for shares of Adamas Pharmaceuticals in a research report issued to clients and investors on Thursday, January 9th, according to Zacks Investment Research. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will earn ($3.84) per share for the year, up from their prior forecast of ($3.85). William Blair also issued estimates for Adamas Pharmaceuticals’ Q4 2019 earnings at ($0.87) EPS, Q1 2020 earnings at ($0.86) EPS, Q2 2020 earnings at ($0.71) EPS, Q3 2020 earnings at ($0.60) EPS, Q4 2020 earnings at ($0.56) EPS and FY2020 earnings at ($2.07) EPS.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). Adamas Pharmaceuticals had a negative net margin of 215.09% and a negative return on equity of 205.30%. The company had revenue of $13.93 million during the quarter, compared to the consensus estimate of $14.36 million.
Several other equities analysts have also weighed in on ADMS. Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Evercore ISI restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Monday, December 9th. Needham & Company LLC reiterated a “hold” rating on shares of Adamas Pharmaceuticals in a report on Tuesday, December 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price (down from $30.00) on shares of Adamas Pharmaceuticals in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $14.63.
Shares of NASDAQ:ADMS traded up $0.16 during trading hours on Monday, hitting $5.67. 348,796 shares of the company’s stock traded hands, compared to its average volume of 576,714. Adamas Pharmaceuticals has a 52 week low of $3.35 and a 52 week high of $12.57. The company has a debt-to-equity ratio of 6.72, a quick ratio of 6.15 and a current ratio of 6.35. The company’s fifty day simple moving average is $4.78 and its two-hundred day simple moving average is $5.40. The company has a market cap of $153.51 million, a price-to-earnings ratio of -1.41 and a beta of 1.66.
Several hedge funds and other institutional investors have recently bought and sold shares of ADMS. Wells Fargo & Company MN lifted its position in shares of Adamas Pharmaceuticals by 144.8% in the second quarter. Wells Fargo & Company MN now owns 22,396 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 13,247 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Adamas Pharmaceuticals by 10.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 46,928 shares of the specialty pharmaceutical company’s stock worth $291,000 after purchasing an additional 4,381 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Adamas Pharmaceuticals in the second quarter worth approximately $25,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Adamas Pharmaceuticals in the second quarter worth approximately $173,000. Finally, BlackRock Inc. lifted its position in shares of Adamas Pharmaceuticals by 5.4% in the second quarter. BlackRock Inc. now owns 2,195,088 shares of the specialty pharmaceutical company’s stock worth $13,609,000 after purchasing an additional 112,278 shares in the last quarter. 51.18% of the stock is owned by institutional investors and hedge funds.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Further Reading: Growth Stocks
Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
